Angry over the high price of a prostate cancer drug, Baltimore officials have filed a lawsuit accusing a Johnson & Johnson (JNJ) unit of using “sham” patent litigation to delay the availability of lower-cost generics, forcing the city to spend millions of dollars unnecessarily.

The lawsuit alleges that Janssen Biotech and its partner, British Technology Group, undertook a “ruse” when seeking a patent for its Zytiga medicine by failing to disclose certain information to the U.S. Patent and Trademark Office. And the move made it possible for the drug maker to deflect generic rivals longer than it might have otherwise.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Kudos to our scribe for a careful reading beyond just the headlines – “both lawsuits use nearly identical language in many sections.”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy